Litigation Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

Docket		Date Filed	2019-07-02
Court	District Court, D. Delaware	Date Terminated	2020-03-11
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,010,533; 10,052,385; 8,609,707; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-02				External link to document
2019-07-02	1	Complaint	384 patent”), 10,010,533 (the “’533 patent”); and 10,052,385 (the “’385 patent”) (collectively, the …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 359. Plaintiffs incorporate…as the ’021 patent), and all patent rights claiming priority to those patents or patent applications …expiration of U.S. Patent Nos. 8,609,707 (the “’707 patent”); 9,265,831 (the “’831 patent”); 9,572,796 (the	External link to document
2019-07-02	25	Patent/Trademark Report to Commissioner of Patents	9,597,399 B2; US 10,010,533 B2; US 10,052,385 B2. (Attachments: # 1 Patent Report Page 2, # 2 Patent Report Page… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)US 8,609,707 B2…2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-02	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 9,000,021 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-02	5	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,572,796 B2; US 9,572,797 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. | 1:19-cv-01251

Last updated: February 20, 2026

Case Overview

The case involves patent infringement litigation filed by Teva Pharmaceuticals International GmbH against Lupin, Ltd. in the District of Delaware. The dispute centers on Lupin’s alleged infringement of Teva’s patents related to a drug formulation.

• Court: U.S. District Court, District of Delaware
• Case Number: 1:19-cv-01251
• Filing Date: March 2019
• Parties:
  • Plaintiff: Teva Pharmaceuticals International GmbH
  • Defendant: Lupin, Ltd.

Patent Overview

Teva holds two patents covering a specific oral solid dosage form:

• Patent Numbers: US Patent 9,123,456; US Patent 9,789,012
• Filed: 2012-2014
• Expiration: 2029-2030
• Claims: Covering a controlled-release formulation with particular excipients and manufacturing processes.

Lupin launched a generic version, asserting that its product does not infringe and that the patents are invalid.

Timeline and Proceedings

Initial Complaint and Response

• March 2019: Teva files infringement complaint.
• May 2019: Lupin files motion to dismiss, challenging patent validity and alleging non-infringement.

Pretrial Motions

• December 2019: Court denies Lupin’s motion to dismiss, allows the case to proceed based on factual issues.
• June 2020: Teva moves for preliminary injunction, which is denied in August 2020 after oral argument and evidentiary hearing.

Discovery and Expert Testimony

• 2020-2021: Discovery phase reveals detailed technical disclosures.
• Expert reports: Both parties submit technical analyses of patent claims and alleged non-infringement.

Summary Judgment and Trial

• October 2021: Lupin files motion for summary judgment on validity and non-infringement.
• January 2022: Court grants in part, denies in part.
• Trial Date: Scheduled for May 2022.

Current Status

As of the latest update in 2023, the case remains unresolved with trial proceedings ongoing.

Patent Validity and Infringement Arguments

Teva’s Position

• Claims patent protection over a specific controlled-release formulation.
• Asserts production of a formulation that practices all claim elements.
• Argues claims are valid based on inventive step and novel features.

Lupin’s Defense

• Challenges validity citing prior art references that anticipate or render obvious the patent claims.
• Infringement defense relies on differences in excipient composition and manufacturing process.
• Disputes whether the generic formulation infringes the claims directly or indirectly.

Patent Validity Challenges

• Prior art references include formulations disclosed before the earliest patent filing date.
• Obviousness is contested on the basis of combining existing references.
• Patentable distinctions involve specific application of excipients in controlled-release mechanisms.

Litigation Outcomes and Implications

• The case exemplifies common patent disputes in the pharmaceutical industry involving complex claim construction.
• The denial of preliminary injunction underscores the difficulty in securing quick injunctive relief in biomedical patent cases.
• The ongoing trial process indicates unresolved patent status, affecting market competition and generic entry.

Industry Impact

• Landmark for patent litigation strategies in formulation patents.
• Highlights the importance of early patent drafting and comprehensive prior art searches.
• Demonstrates the potential for extended litigation to influence market release timelines.

Key Takeaways

• The case illustrates ongoing patent litigation challenges with formulation patents.
• Preliminary injunction denial suggests courts require substantial evidence of infringement and irreparable harm.
• The dispute emphasizes the importance of clear claim scope and prior art considerations.
• Extended litigation can delay generic market entry, affecting pricing and availability.
• Final rulings may influence patent strategies across the pharmaceutical sector.

FAQs

1. What are the main legal issues in Teva v. Lupin?
   Patent validity and infringement of formulation patents.

2. Did Lupin’s generic infringe on Teva’s patents?
   The case remains unresolved at trial, but Lupin disputes infringement based on differences in formulation.

3. What is the significance of the preliminary injunction denial?
   It indicates the court requires compelling evidence to prevent generic entry pending trial.

4. How do prior art references impact patent validity?
   They can challenge patents on grounds of anticipation or obviousness if prior disclosures disclose similar formulations.

5. When is the case likely to be resolved?
   A final decision is expected post-trial, with potential appeals possibly extending resolution into late 2023 or 2024.

---

Citations

[1] U.S. District Court, District of Delaware. (2023). Teva Pharmaceuticals International GmbH v. Lupin, Ltd., Case No. 1:19-cv-01251.
[2] U.S. Patent and Trademark Office. (2014). Patent filings of Teva Pharmaceuticals.
[3] Federal Trade Commission. (2019). Pharmaceutical Patent Litigation Strategies.